Key features and details | |
Cat. No. | MABL-561 |
Name | Anti-BTLA mAbs |
Clone No. | AFD- HMBT-6B2 |
From | Recombinant Antibody |
Isotype | Engineer antibody |
Application | Blocking, functional assays, immunoblot, IP, WB, FC |
Species Reactivity | Mouse |
Basic Information | |
Specificity | This antibody is specific for B and T lymphocyte attenuator (BTLA), which functions as a negative regulator of T cell activation and proliferation, and attenuates B cell proliferation upon associating with its known ligand, herpes virus entry mediator (HVEM). |
Alternative Name | CD272; B and T lymphocyte attenuator; B- and T-lymphocyte attenuator; B and T lymphocyte associated protein; B- and T-lymphocyte-associated protein; BTLA1; FLJ16065; MGC129743 |
UniProt | Q7TSA3 |
Immunogen | This antibody was raised by immunising Armenian hamsters with mouse BTLA: Fc fusion protein. |
Application Notes | This antibody has been used in immunoblot analyses to confirm that B and T lymphocyte attenuator (BTLA) regulates T cell activation through interaction with herpesvirus entry mediator (HVEM) (Sedy et al, 2005), as well as in FACS and yeast display technology to demonstrate that BTLA exhibits structural and expression polymorphisms and is highly induced in anergic CD4+ T Cells (Hurchla et al, 2005). In a mouse conjunctivitis model, treatment with this antibody during the induction phase has been shown to decrease B-cell population, upregulate Th2 cytokine production and increase the conjunctival eosinophile numbers (Ishida et al, 2012). However, treatment with this antibody during the effector phase does not affect the development of experimental conjunctivitis (Ishida et al, 2012). |
Antibody First Published | Waka Ishida et al. B and T lymphocyte attenuator regulates the development of antigen-induced experimental conjunctivitis. Graefes Arch Clin Exp Ophthalmol. 2012 Feb;250(2):289-95. PMID:21779950 |
Note on publication | Describe the use of this antibody, together with the anti-HVEM antibody, to investigate the roles that B and T lymphocyte attenuator (BTLA) and herpesvirus entry mediator (HVEM) play in the development of antigen-induced experimental conjunctivitis (EC). |
COA Information （For reference only, actual COA shall prevail） | |
Size | 100 μg Purified antibody. |
Concentration | 1 mg/ml. |
Purification | Protein A affinity purified |
Buffer | PBS with 0.02% Proclin 300. |
Concentration | 1 mg/ml. |
Storage Recommendation | Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C. |
